Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)

The purpose of this research study is to study the safety and immune response of people who receive a personalized dendritic cell vaccine with the intention of stimulating the immune system to react to lung cancer cells.

Study Overview

• Status: Withdrawn
• Conditions: Non-Small Cell Lung Cancer; Nonsmall Cell Lung Cancer; Carcinoma, Non-Small-Cell-Lung
• Intervention / Treatment: Drug: Cyclophosphamide; Procedure: Apheresis; Procedure: Standard of care surgery; Biological: Personalized mature dendritic cell vaccine

Detailed Description

Tumor vaccines represent a promising area of clinical investigation in solid tumors based on evidence of clinical activity and minimal toxicity. The underlying hypothesis of this research is that immunization against tumor neoantigens is effectively required to elicit antigen-reactive T cells capable of recognizing and eliminating cancer. Moreover, both quantitative and qualitative improvements in CD8 immunity are necessary (but not sufficient) for clinical response and improved survival. The goal of this study is to build on our prior clinical trial results in melanoma by studying the immune response to tumor neoantigens in patients with stage 1 NSCLC.

• Study Type: Interventional
• Phase: Early Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients with completely resected stage I non-small cell lung cancer who are not considered for adjuvant post operative therapy.
• Age ≥ 18 years.
• ECOG performance status 0-1.
• HLA-A2 positive.

• Required initial laboratory values (submitted within 14 days prior to registration):

  • WBC > 3,000/mm3
  • Hg ≥ 9.0 gm/dL
  • Platelets >75,000/mm3
  • Serum bilirubin < 2.0 mg/dL
  • Serum creatinine < 2.0 mg/dL
• Sexually active women of childbearing potential must use effective birth control during the trial and for at least two months following the trial, and sexually active men must be willing to avoid fathering a new child while receiving therapy.
• Able to understand and willing to sign an IRB-approved written informed consent document.

Exclusion Criteria:

• Prior treatment with cytotoxic chemotherapy
• Prior treatment with targeted therapy or immunotherapy.
• Active untreated CNS metastasis.
• Active infection.
• Prior malignancy (except non-melanoma skin cancer) within 3 years.
• Pregnant or nursing.
• Concurrent treatment with systemic corticosteroids; local (inhaled or topical) steroids are permitted.
• Known allergy to eggs.
• Prior history or uveitis or autoimmune inflammatory eye disease.
• Known positivity for hepatitis B sAg, hepatitis C antibody, or HIV antibody.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Surgery/Apheresis/Cyclophosphamide/Vaccine; Standard of care surgery; Apheresis (between Day -28 and Day -7) approximately 12 weeks after surgery; Cyclophosphamide 300 mg/m^2 intravenously (Day -4); Personalized vaccine (Day 1); Booster dose of personalized vaccine (Day 43); Booster dose of personalized vaccine (Day 85)	Drug: Cyclophosphamide; Other Names: Cytoxan®; Procedure: Apheresis; Procedure: Standard of care surgery; Biological: Personalized mature dendritic cell vaccine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Immunological response as measured by increased numbers of peptide specific CD8+ T cells as calculated by the tetramer assay	-Blood for immunological response is drawn every week from Dose #1 to 6 weeks after Dose #3 (Day 1 to Day 126 = Week 18 and then every 4 weeks until Day 365)	1 year
Safety and tolerability of vaccine as measured by adverse events experienced and graded by NCI CTCAE Version 4.0	Safety will be closely monitored after vaccination. Patients will be observed for 2 hours after the first dose and vital signs recorded every 30 minutes during that time period beginning at the start of the infusion. For each dose thereafter, patients will be observed in the treatment area for 30 minutes after the infusion. The following parameters will be assessed: Local signs and symptoms; Systemic signs and symptoms; Laboratory evaluations; Adverse and serious adverse events; Toxicity will be graded according to the NCI's CTCAE version 4.0.	30 days after last vaccine (approximately Day 115)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to progression (TTP)	These patients have been completed resected so there is no tumor response to monitor. CT scans evaluating for progression will be performed at baseline, following the third vaccine dose, and as per routine care during follow-up (generally every 3 months for the first year and every 6 months for the next 4 years thereafter).	5 years

Collaborators and Investigators

• Sponsor: Washington University School of Medicine

Publications and helpful links

Helpful Links

• Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Study record dates

Study Major Dates

• Study Start: July 1, 2016
• Primary Completion (Anticipated): October 1, 2019
• Study Completion (Anticipated): October 1, 2023

Study Registration Dates

• First Submitted: February 4, 2015
• First Submitted That Met QC Criteria: April 16, 2015
• First Posted (Estimate): April 17, 2015

Study Record Updates

• Last Update Posted (Estimate): July 18, 2016
• Last Update Submitted That Met QC Criteria: July 14, 2016
• Last Verified: July 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Cyclophosphamide
• Other Study ID Numbers: 15-x043